Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
doi: 10.2147/dhps.s6920
REFERENCES 1.Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, et al
Jeffrey Flier, former Dean at Harvard Medical School, writes in STAT on How Pfizer ended up passing on my GLP-1 work back in the early 90s. Flier kicks off with Despite extremely promising results, Pfizer, the major funder of the work in alliance with California Biotechnology, abandoned the effort around 1991 after mistakenly concluding that the GLP-1 therapeutic approach was not worth continuing. He states that he is not trying to take credit for the GLP-1 market, rather that the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. The article describes the early stages of drug development and testing from 1987, with Pfizer against an injectable GLP-1 version, and a focus on a way to deliver GLP-1 via transnasal, transcutaneous, or oral administration
Increased demand for glutathione can also cause low levels
